AsymBio

AsymBio operates as a strategic business unit of the Asymchem Group, providing specialized biopharmaceutical CDMO services. The company focuses on the development and manufacturing of novel conjugated drugs, monoclonal antibodies, and recombinant protein therapeutics. By leveraging advanced technology platforms, AsymBio supports global biopharmaceutical clients through the entire drug development lifecycle, ranging from early-stage research and process development to full-scale commercial manufacturing. Their technical expertise encompasses developability assessment, analytical science, quality control, and regulatory affairs, ensuring high-quality standards for complex biological products.

With a workforce of 500-1,000 employees, AsymBio maintains a robust operational footprint to meet the rigorous demands of the global pharmaceutical market. The company operates from its primary facility located in Woburn, Massachusetts, serving as a central hub for its North American operations. This facility integrates comprehensive one-stop service capabilities, allowing for seamless transitions between clinical phases and commercial production. AsymBio’s commitment to technical excellence and project management facilitates innovation, helping clients navigate the complexities of drug commercialization while maintaining strict adherence to global regulatory requirements.

As a key player in the biopharmaceutical manufacturing sector, AsymBio continues to expand its service offerings to address the evolving needs of the industry. The organization prioritizes strategic partnerships, utilizing its extensive project experience to accelerate time-to-market for novel therapeutics. Meet AsymBio's team to learn about their leadership and the technical expertise driving their operational success. By focusing on high-value contract development and manufacturing services, the company remains a reliable partner for organizations seeking to advance their drug pipelines from initial discovery to final marketView more...